ACUR - Acura Pharmaceuticals Stock Price, News & Analysis

$0.42 0.00 (0.00 %)
(As of 11/23/2017 04:44 AM ET)
Previous Close$0.42
Today's Range$0.42 - $0.42
52-Week Range$0.40 - $1.40
Volume236 shs
Average Volume13,058 shs
Market Capitalization$8.77 million
P/E RatioN/A
Dividend YieldN/A

About Acura Pharmaceuticals (OTCMKTS:ACUR)

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol

Industry Drug Delivery
  • Previous Symbol: NASDAQ:ACUR
  • CUSIP00509L70


    Debt-to-Equity Ratio0.44%
    Current Ratio1.23%
    Quick Ratio1.23%


    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$4.46 million
    Price / Sales1.96
    Cash FlowN/A
    Price / CashN/A
    Book Value$0.08 per share
    Price / Book5.26


    Annual DividendN/A
    Dividend YieldN/A


    Trailing EPS($0.14)
    Net Income$-7,380,000.00
    Net Margins-36.20%
    Return on Equity-231.18%
    Return on Assets-31.56%


    Outstanding Shares20,800,000

    Frequently Asked Questions for Acura Pharmaceuticals (OTCMKTS:ACUR)

    What is Acura Pharmaceuticals' stock symbol?

    Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."

    How were Acura Pharmaceuticals' earnings last quarter?

    Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its quarterly earnings results on Monday, November, 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. The specialty pharmaceutical company earned $0.08 million during the quarter. Acura Pharmaceuticals had a negative net margin of 36.20% and a negative return on equity of 231.18%. View Acura Pharmaceuticals' Earnings History.

    Who are some of Acura Pharmaceuticals' key competitors?

    Who are Acura Pharmaceuticals' key executives?

    Acura Pharmaceuticals' management team includes the folowing people:

    • Robert B. Jones, President, Chief Executive Officer, Director (Age 58)
    • Peter A. Clemens, Chief Financial Officer, Senior Vice President, Secretary (Age 64)
    • Robert A. Seiser CPA, Vice President, Corporate Controller and Treasurer (Age 53)
    • J. Bradley Rivet, Vice President - Marketing (Age 63)
    • Albert W. Brzeczko Ph.D., Vice President -Technical Affairs (Age 60)
    • James F. Emigh, Vice President - Corporate Development (Age 61)
    • George K. Ross, Independent Director (Age 75)
    • William G. Skelly, Independent Director (Age 66)
    • Immanuel Thangaraj, Independent Director (Age 45)
    • Bruce F. Wesson, Independent Director (Age 74)

    How do I buy Acura Pharmaceuticals stock?

    Shares of Acura Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Acura Pharmaceuticals' stock price today?

    One share of Acura Pharmaceuticals stock can currently be purchased for approximately $0.42.

    How big of a company is Acura Pharmaceuticals?

    Acura Pharmaceuticals has a market capitalization of $8.77 million and generates $4.46 million in revenue each year. The specialty pharmaceutical company earns $-7,380,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Acura Pharmaceuticals employs 15 workers across the globe.

    How can I contact Acura Pharmaceuticals?

    Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]

    MarketBeat Community Rating for Acura Pharmaceuticals (ACUR)

    Community Ranking:  2.9 out of 5 (star star)
    Outperform Votes:  107 (Vote Outperform)
    Underperform Votes:  80 (Vote Underperform)
    Total Votes:  187
    MarketBeat's community ratings are surveys of what our community members think about Acura Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Acura Pharmaceuticals (OTCMKTS:ACUR)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
    Consensus Rating:N/A (Score: NaN)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Acura Pharmaceuticals (OTCMKTS:ACUR)

    Price Target History for Acura Pharmaceuticals (OTCMKTS:ACUR)

    Analysts' Ratings History for Acura Pharmaceuticals (OTCMKTS:ACUR)

    DateFirmActionRatingPrice TargetDetails
    10/21/2016FBR & CoReiterated RatingOutperform$10.00View Rating Details
    10/18/2016Roth CapitalSet Price TargetBuy$6.00View Rating Details
    (Data available from 11/23/2015 forward)


    Earnings History and Estimates Chart for Acura Pharmaceuticals (OTCMKTS:ACUR)

    Earnings by Quarter for Acura Pharmaceuticals (OTCMKTS:ACUR)

    Earnings History by Quarter for Acura Pharmaceuticals (OTCMKTS ACUR)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    11/13/2017Q3 2017($0.12)$0.08 millionViewN/AView Earnings Details
    8/14/2017Q2 2017($0.11)($0.18)$0.09 millionViewN/AView Earnings Details
    5/12/2017Q1 2017($0.11)$0.03$0.34 million$2.72 millionViewN/AView Earnings Details
    11/14/2016Q3($0.27)($0.19)$0.23 million$0.22 millionViewN/AView Earnings Details
    8/8/2016Q2($0.28)($0.28)$0.19 million$0.26 millionViewN/AView Earnings Details
    5/2/2016Q116($0.26)($0.28)$0.15 million$0.22 millionViewN/AView Earnings Details
    2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details
    8/3/2015Q215($0.02)($0.05)$2.90 million$0.34 millionViewN/AView Earnings Details
    5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details
    3/2/2015Q414($0.09)($0.06)$0.05 million$0.53 millionViewN/AView Earnings Details
    11/3/2014Q3 2014($0.08)($0.06)$0.05 million$0.15 millionViewN/AView Earnings Details
    3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details
    8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details
    3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)


    Earnings Estimates for Acura Pharmaceuticals (OTCMKTS:ACUR)

    No earnings estimates for this company have been tracked by


    Dividend History for Acura Pharmaceuticals (OTCMKTS:ACUR)
    No dividend announcements for this company have been tracked by

    Insider Trades

    Insider Trading and Institutional Ownership History for Acura Pharmaceuticals (OTCMKTS ACUR)

    Insider Ownership Percentage: 5.60%
    Institutional Ownership Percentage: 9.41%
    Insider Trades by Quarter for Acura Pharmaceuticals (OTCMKTS:ACUR)
    Insider Trades by Quarter for Acura Pharmaceuticals (OTCMKTS:ACUR)

    Insider Trades by Quarter for Acura Pharmaceuticals (OTCMKTS ACUR)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    8/29/2017Albert W BrzeczkoVPBuy10,800$0.47$5,076.00View SEC Filing  
    6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  
    1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  
    5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  
    5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  
    5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  
    5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  
    5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  
    5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  
    5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  
    5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  
    5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  
    3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  
    2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  
    2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  
    11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  
    10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  
    8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  
    7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  
    7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  
    7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  
    6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  
    6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  
    6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  
    6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  
    6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  
    6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  
    6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  
    6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  
    6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  
    5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  
    5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  
    5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  
    5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  
    5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  
    5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  
    5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  
    5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  
    5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  
    5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  
    5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  
    5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  
    4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  
    3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  
    (Data available from 1/1/2013 forward)


    Latest Headlines for Acura Pharmaceuticals (OTCMKTS ACUR)


    Social Media



    Acura Pharmaceuticals (OTCMKTS ACUR) Chart for Thursday, November, 23, 2017
    Loading chart…

    This page was last updated on 11/23/2017 by Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.